Disease · MONDO_0006325
Trials13
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 13 of 13
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01835145 | Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery | Phase 2 | 47 | 2019-04-26 | Recurrent Uveal Melanoma, Stage III Uveal Melanoma AJCC v7, Stage IIIA Uveal Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Uveal Melanoma AJCC v7 | CABOZANTINIB, DACARBAZINE, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00925132 | Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat | Phase 1/2 | 39 | 2017-07-02 | Metastatic Melanoma | DECITABINE, PANOBINOSTAT, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01814046 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma | Phase 2 | 24 | 2017-07-24 | Metastatic Ocular Melanoma, Metastatic Uveal Melanoma | ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE | Its record names the disease | ClinicalTrials.gov |
| NCT00109005 | Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma | Phase 2 | 17 | 2012-10-30 | Melanoma | LENALIDOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00482911 | Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma | Phase 2 | 12 | 2012-11-14 | Intraocular Melanoma, Malignant Conjunctival Neoplasm | CYCLOPHOSPHAMIDE, LENALIDOMIDE, SUNITINIB MALATE | Its record names the disease | ClinicalTrials.gov |
| NCT03850691 | Radiation and Combination Immunotherapy for Melanoma | Phase 2 | 4 | 2023-03-03 | Metastatic Melanoma | ALDESLEUKIN, IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03919292 | Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca | Phase 1/2 | 80 | Solid Tumor, Adult | DIVALPROEX SODIUM, NERATINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT00489944 | Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma | Phase 2 | 50 | Intraocular Melanoma | CISPLATIN, SUNITINIB MALATE, TAMOXIFEN CITRATE | Its record names the disease | ClinicalTrials.gov | |
| NCT05022901 | An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma | Phase 3 | 30 | Metastatic Ocular Melanoma, Metastatic Uveal Melanoma | MELPHALAN | Its record names the disease | ClinicalTrials.gov | |
| NCT00085306 | Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma | Phase 2 | 21 | Stage IV Melanoma, Recurrent Melanoma | INTERFERON BETA | Its record names the disease | ClinicalTrials.gov | |
| NCT00421317 | Imatinib in Adult Patients With Metastatic Ocular Melanoma | Phase 2 | 13 | Melanoma | IMATINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT00621439 | Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye | Not applicable | 0 | Ocular Melanoma | INTERFERON ALFA-2B | Its record names the disease | ClinicalTrials.gov | |
| NCT01728051 | Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver | Metastatic Liver Cancer, Ocular Melanoma, Cutaneous Melanoma | MELPHALAN | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006325/trials